We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $5.34B
1-Year Est. Return 380.18%
This Fund
S&P 500
This Quarter Est. Return
+40.65%
1 Year Est. Return
+380.18%
3 Year Est. Return
+803.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.34B
AUM Growth
+$446M
Cap. Flow
-$643M
Cap. Flow %
-12.03%
Top 10 Hldgs %
75.21%
Holding
42
New
7
Increased
12
Reduced
7
Closed
14

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$145M
2
SYRE icon
Spyre Therapeutics
SYRE
+$137M
3
GMAB icon
Genmab
GMAB
+$137M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$98.3M
5
MBX
MBX Biosciences
MBX
+$87.6M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$663M
2
PCVX icon
Vaxcyte
PCVX
+$145M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$142M
4
TERN
Terns Pharmaceuticals
TERN
+$117M
5
CYTK icon
Cytokinetics
CYTK
+$97.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$45.2B
$1.19B 22.31%
6,361,323
-294,380
-4% -$43M
NUVL
2
DELISTED
Nuvalent
NUVL
$732M 13.7%
5,924,433
+600,000
+11% +$64.5M
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.56B
$415M 7.77%
10,215,455
+2,850,417
+39% +$98.3M
GMAB icon
4
Genmab
GMAB
$21.1B
$361M 6.76%
13,133,131
+5,165,295
+65% +$137M
SYRE icon
5
Spyre Therapeutics
SYRE
$7.69B
$341M 6.38%
3,840,778
+1,883,512
+96% +$137M
APGE icon
6
Apogee Therapeutics
APGE
$10.2B
$209M 3.92%
1,576,385
+228,142
+17% +$20.6M
ORKA
7
Oruka Therapeutics
ORKA
$6.02B
$204M 3.82%
2,144,526
-175,790
-8% -$11.7M
TNGX icon
8
Tango Therapeutics
TNGX
$3.84B
$199M 3.72%
6,357,523
+2,347,844
+59% +$58M
BLTE
9
Belite Bio
BLTE
$6.89B
$190M 3.55%
1,232,877
+118,093
+11% +$18.1M
ERAS icon
10
Erasca
ERAS
$5.69B
$175M 3.28%
9,550,000
-842,702
-8% -$12.1M
TARS icon
11
Tarsus Pharmaceuticals
TARS
$3.65B
$175M 3.27%
2,775,649
+213,495
+8% +$13.6M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$35.4B
$144M 2.71%
+480,000
New +$145M
INSM icon
13
Insmed
INSM
$27.7B
$141M 2.65%
1,325,977
+71,489
+6% +$8.66M
MBX
14
MBX Biosciences
MBX
$2.96B
$138M 2.59%
+2,508,015
New +$87.6M
PCVX icon
15
Vaxcyte
PCVX
$9.1B
$124M 2.32%
2,127,852
-2,665,168
-56% -$145M
VRDN icon
16
Viridian Therapeutics
VRDN
$2.6B
$124M 2.31%
6,723,788
+3,574,895
+114% +$57.6M
OLMA icon
17
Olema Pharmaceuticals
OLMA
$939M
$108M 2.03%
8,670,576
+650,000
+8% +$8.71M
JBIO
18
Jade Biosciences
JBIO
$1.26B
$63.5M 1.19%
+2,857,405
New +$59.6M
TYRA icon
19
Tyra Biosciences
TYRA
$1.48B
$58.4M 1.09%
1,828,607
-226,384
-11% -$7.49M
ASMB icon
20
Assembly Biosciences
ASMB
$736M
$42.7M 0.8%
1,553,748
+888,497
+134% +$24.2M
EYPT icon
21
EyePoint Inc
EYPT
$394M
$41.3M 0.77%
2,890,397
-252,040
-8% -$3.37M
ACHV icon
22
Achieve Life Sciences
ACHV
$855M
$32.3M 0.61%
+4,951,856
New +$23.6M
VOR icon
23
Vor Biopharma
VOR
$1.43B
$32.2M 0.6%
1,750,000
– –
MPLT
24
MapLight Therapeutics
MPLT
$609M
$24.6M 0.46%
+685,852
New +$19.7M
KARD
25
Kardigan Inc
KARD
$1.94B
$21.5M 0.4%
+900,000
New +$20.8M
1
2

Similar funds

FFB
First Financial Bankshares Abilene, Texas $5.34B AUM 28.75% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
CAU
Caxton Associates (UK) London $5.33B AUM 59.38% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $5.32B AUM 22.63% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
Twin Tree Management
Twin Tree Management Dallas, Texas $5.31B AUM 55.82% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Paradigm Biocapital Advisors held 42 positions worth $5.34B, up 9.1% from $4.89B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Paradigm Biocapital Advisors withdrew a net $643M in Q2 2026, closing 14 positions and reducing 7 holdings. Its most notable exit was Arcellx, an estimated $663M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Paradigm Biocapital Advisors opened a new position in Alnylam Pharmaceuticals worth $144M.

  • Paradigm Biocapital Advisors's largest Q2 2026 buy was Alnylam Pharmaceuticals: 480,000 shares worth $144M.
  • Paradigm Biocapital Advisors added most to Spyre Therapeutics in Q2 2026, an estimated $137M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2026 reduction was Vaxcyte, cutting an estimated $145M.
  • Paradigm Biocapital Advisors fully exited Arcellx in Q2 2026, selling an estimated $663M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 75% of its $5.34B portfolio in Q2 2026.
  • Paradigm Biocapital Advisors opened 7 new positions and closed 14 in Q2 2026.
  • Paradigm Biocapital Advisors's portfolio value rose 9.1% quarter-over-quarter to $5.34B.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.